Skip to content

Activists Urge Otsuka to Provide Access to TB Drug

Tuberculosis (TB) activists interrupted Otsuka’s symposium at the 45th Conference on World Lung Health, calling for widespread registration of and immediate broad compassionate use access to delamanid, Otsuka’s new drug to treat multidrug-resistant TB (MDR-TB).
Read more

Tuberculosis Research at Risk as Big Pharma Shutters Programs

Worldwide governments, foundations, and companies invested US$676.7 million in research to develop new drugs, vaccines, and diagnostics against tuberculosis (TB) in 2013—barely one-third of the US$2 billion that experts estimate the world must spend each year to end the global TB epidemic—according to an analysis released today by Treatment Action Group.
Read more

2014 Report on TB Research Funding Trends

2014 Report on Tuberculosis Research Funding Trends, 2005–2013. 2nd Edition May 18, 2015 By Mike Frick Edited by Mark Harrington and Andrea Benzacar From the Executive Summary Reader beware: funding data presented in this report may be less encouraging than…

Read more

Generics vs. the Giant

For people with drug-resistant tuberculosis (DR-TB), generic linezolid may be a lifesaver. But only if quality-assured versions are available and affordable Erica Lessem As new drugs bedaquiline and delamanid offer renewed hope of treating DR-TB, doctors and programs are faced…

Read more

Safeguarding against Stock-Outs

The time has come for U.S. tuberculosis programs to have full access to the Stop TB Partnership’s Global Drug Facility procurement and stockpile safety nets Kenyon Farrow Generic drugs can be credited with saving millions of lives by allowing for…

Read more

An Activist’s Guide to Linezolid (Zyvox)

By Erica Lessem and Lauren Volpert September 2014 I. Introduction Increasingly drug-resistant forms of tuberculosis (TB) are becoming more common worldwide, and few medicines are available to treat them.1 Newly developed TB drugs, such as bedaquiline and delamanid, offer some…

Read more
Back To Top